No impact of rifamycin selection on tuberculosis treatment outcome in HIV coinfected patients

AIDS. 2013 Jan 28;27(3):481-4. doi: 10.1097/QAD.0b013e32835a67fb.

Abstract

Rifabutin has been substituted for rifampicin when treating tuberculosis (TB)/HIV coinfection. However, despite reports of anti-TB treatment failure and acquired rifamycin resistance, long-term clinical outcome data are lacking. Observational analyses performed in a UK TB/HIV cohort demonstrated no difference in severe adverse events, anti-TB treatment completion, relapse frequency or subsequent rifamycin resistance when rifampicin and rifabutin were compared, using different combinations of antiretroviral therapy. Our data support the wider use of rifabutin in TB/HIV coinfection.

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy*
  • Adult
  • Antitubercular Agents / therapeutic use*
  • Coinfection
  • Drug Resistance, Bacterial
  • Female
  • HIV Infections / drug therapy
  • Humans
  • Male
  • Retrospective Studies
  • Rifabutin / therapeutic use*
  • Rifamycins / therapeutic use*
  • Treatment Outcome
  • Tuberculosis, Pulmonary / drug therapy*

Substances

  • Antitubercular Agents
  • Rifamycins
  • Rifabutin
  • rifamycin SV